Takeda Pharmaceutical Co Ltd
Oveporexton (TAK-861)
narcolepsy type 1
Countdown
86days
FDA decision · ~ Sep 30, 2026 estimated
What's at stake
The FDA's approval decision on Oveporexton (TAK-861) for narcolepsy type 1 is due ~ Sep 30, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 6-K
verified 11h ago
“The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year”